NeuroRepair, Inc. owns the exclusive rights to an exciting patented process, the basis of which was originally developed at the University of California. It employs an endogenous, 50 amino acid protein called Transforming Growth Factor-alpha (TGFα). In animal experiments where TGFα has been administered to an injured brain, results have shown that it can restore 100% of function lost to stroke, even after the stroke injury has fully stabilized and is classified as “chronic.” Employing NeuroRepair’s patented process, this naturally occurring protein can also be administered in an entirely noninvasive way (intranasally), eliminating the risks of surgery.

NeuroRepair is a small company that has been 100% funded by its founder, Matthew Klipstein. After suffering a brain injury in a sports accident, Klipstein was told by neurologists that his injury was hopeless and he would never fully recover. Mr. Klipstein then formed and personally funded NeuroRepair, Inc. to pursue research in order to find a cure for neurological injury, from which tens of millions of Americans suffer. Its research has been conducted under the direction of world-renowned neuroscientist Dr. James Fallon at a leading research university, the University of California, Irvine. While the research is still “early stage” (animals only), the science is undeniably valid and the prospects extremely promising.


The Problem: Brain Injury and Neurodegenerative Disorders

Central nervous system injury and neurological diseases are recognized as an increasing health and social problem in America and throughout the world, one that can be expected to grow in numbers and cost as the population ages.

According to the Centers for Disease Control and Prevention, stroke is the third leading cause of death in the United States and the primary cause of disabilities in adults. Throughout the country, strokes occur at the rate of one per minute. More than 700,000 Americans experience a stroke each year and more than 157,000 of those will die. The estimated cost of stroke to the nation each year is 57.9 billion dollars.

Strokes can occur at any age (even before birth). However, people over age 65 experience almost three fourths of all strokes. The death rate from stroke in African Americans is almost double that of Caucasians.

The lifetime direct medical cost per person suffering first strokes occurring in 1990 is estimated to be more than $228,000 for hemorrhagic stroke, and over $123,500 for ischemic stroke.
Source: 1996 American Heart Association

Parkinson’s disease (PD) involves the loss of dopamine-producing brain cells, and belongs to a group of conditions called motor system disorders.

In the United States alone, at least 500,000 people are believed to suffer from Parkinson’s disease, with about 50,000 new cases reported annually.
Source: 2004 National Institute of Neurological Disorders and Stroke report

It is unknown how many Americans presently suffer from the effects of traumatic brain injury; however, according to the Centers for Disease Control and Prevention, each year an estimated 1.7 million Americans sustain a traumatic brain injury. Of them:

  • 52,000 die,
  • 275,000 are hospitalized, and
  • 1.365 million, nearly 80%, are treated and released from an emergency department without realizing that they may have a lasting, or even permanent, injury.

Source: Centers for Disease Control and Prevention report 2012
The Answer: Presently There is No FDA-approved Therapeutic, but NeuroRepair
May Have an Answer

Among the relatively few researchers who are working on finding a cure for neurological disorders or brain injuries, such as stroke, virtually all employ either embryonic stem cells, or some variant of Induced Pluripotent Stem Cells (IPSC)*. There are drawbacks to these solutions: embryonic stem cell research can be controversial, and in the case of both embryonic stem cells and IPSC, almost all of the proposed solutions being researched require surgery.

In marked contrast to others, NeuroRepair does not resort to transplantation of cells. It employs an endogenous 50 amino acid protein called Transforming Growth Factor-alpha (TGFα) to stimulate neurogenesis (the adult mammalian brain’s latent ability to repair itself and restore function, reversing damage from virtually any kind of injury or disease). Until recently this elegant mechanism remained undiscovered and medicine taught that it did not exist. At NeuroRepair, working in cooperation with the University of California, we have demonstrated that neurogenesis is real and stunningly effective, with a bit of patented proprietary help. In animal studies, our patented process has shown stunning success in restoring brain function lost to Stroke or Parkinson’s Disease. This places NeuroRepair, Inc.’s patented intellectual property far ahead of other solutions, in terms of both potential efficacy and safety.

*IPSC are cells, such as bone marrow cells, that can be chemically manipulated in vitro to mimic adult stem cells. In experimentation, these cells are generally administered via stereotactic surgery directly into the brain. At NeuroRepair, we see two potentially serious problems with surgical administration of IPSCs: (1) surgery, and (2) IPSC cells. Although stereotactic surgery has a very good record for safety, brain surgery has inherent risk. And, while great care may be taken to render the cells used for such treatment allogeneic (not likely to induce an immunological response), cells are complex. Therefore, even with great care, prevention of a potentially life-threatening immunological response cannot be assured.